In Q3 2023, RA Capital Management held 1 positions worth $37.6M. They exited 45. Their largest holding was CTKB ($37.6M). Portfolio value shrank -99.1% versus the prior quarter.
Frequently asked questions
What stocks did RA Capital Management own in Q3 2023?
RA Capital Management held 1 biotech stocks in their 13F portfolio in Q3 2023. Their top positions include CTKB. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was RA Capital Management's portfolio worth in Q3 2023?
RA Capital Management's tracked biotech portfolio was worth $37.6M across 1 positions, with total assets under management of approximately $10B. Portfolio values are based on 13F filings with the SEC.
What did RA Capital Management buy in Q3 2023?
RA Capital Management did not initiate any new positions in Q3 2023, but increased 0 existing holdings.
What did RA Capital Management sell in Q3 2023?
RA Capital Management fully exited 45 positions in Q3 2023, including CLDX, ENTX, RCKT, WHWK, HOWL and 40 more. They also trimmed 1 existing positions.
Is RA Capital Management a biotech fund?
Crossover biotech fund that invests from late-stage private through public markets. Known for rigorous scientific analysis and the "biotech social contract" framework. Kolchinsky, a virologist by training, emphasizes understanding drug pricing dynamics and long-term value creation in biotech.
Want AI analysis, insider signals, and catalyst overlays for RA Capital Management?
View latest RA Capital Management portfolio →